Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 2 de 2
Filtrer
Plus de filtres











Base de données
Gamme d'année
1.
Braz J Med Biol Res ; 50(12): e6424, 2017 Oct 19.
Article de Anglais | MEDLINE | ID: mdl-29069228

RÉSUMÉ

Studies suggest that brain-derived neurotrophic factor (BDNF) and the hypothalamic-pituitary-adrenal (HPA) axis modulate dopaminergic activity in response to nicotine and that the concentrations of BDNF and cortisol seem to be dependent on the amount and duration of smoking. Therefore, we investigated BDNF and cortisol levels in smokers ranked by daily cigarette consumption. Twenty-seven adult males (13 non-smokers and 14 smokers) participated in the study. The smokers were divided in two groups: light (n=7) and heavy smokers (n=7). Anthropometric parameters and age were paired between the groups, and plasma BDNF and salivary cortisol levels were measured. Saliva samples were collected on awakening, 30 min after awakening, at 10:00 and 12:00 am, 5:00 and 10:00 pm. Additionally, cotinine serum levels were measured in smokers. Heavy smokers had higher mean values of BDNF compared to the control group (P=0.01), whereas no difference was observed in light smokers. Moreover, heavy smokers presented lower cortisol levels in the last collection (10:00 pm) than the control group (P=0.02) and presented statically higher values of cotinine than the light smokers (P=0.002). In conclusion, changes in BDNF and cortisol levels (10:00 pm) appear to be dependent on heavy cigarette smoking and can be involved in activation and in the relationship between the mesolimbic system and the HPA axis.


Sujet(s)
Facteur neurotrophique dérivé du cerveau/sang , Hydrocortisone/analyse , Fumer/métabolisme , Adulte , Analyse de variance , Études cas-témoins , Test ELISA , Humains , Techniques immunoenzymatiques , Mâle , Nicotine/effets indésirables , Nicotine/métabolisme , Valeurs de référence , Salive/composition chimique , Fumer/effets indésirables , Statistique non paramétrique , Facteurs temps , Produits du tabac/effets indésirables
2.
Auton Autacoid Pharmacol ; 27(2): 123-9, 2007 Apr.
Article de Anglais | MEDLINE | ID: mdl-17391282

RÉSUMÉ

1. We investigated the influence of bromocriptine (BR) chronic treatment in the autonomic adjustments to energetic metabolism during restraint stress (RS). To achieve this, Wistar male rats were chronically treated with BR before the application of RS. The rats were divided into two groups: those treated with BR and control rats, treated with saline. 2. Chronic treatment with BR did not affect rat growth and induced a 20% higher basal plasma glucose concentration. During RS, BR rats presented higher plasma glucose concentrations than the control animals. Despite this, the 30-min analysis of the areas under the glucose curve showed that the control rats presented a hyperglycemic response to RS two-fold greater than the BR rats. 3. RS induced an increase in plasma lactate concentration in both groups of rats; however, the 30-min analyses under the lactate curves showed that BR rats presented a lactate response to RS three times higher than control rats. 4. RS induced an increase in plasma free fatty acids (FFA) concentration in both groups; however, plasma FFA concentration of BR rats returned to the basal values at the end of RS. In contrast, in the control group, this concentration continued to rise until the end of RS. 5. The results showed that BR chronic treatment shifts the balance of substrate utilization in response to RS, suggesting that the essential role of lactate in the metabolism homeostasis may be altered by chronic BR treatment.


Sujet(s)
Bromocriptine/pharmacologie , Agonistes de la dopamine/pharmacologie , Contention physique , Stress physiologique/métabolisme , Animaux , Glycémie/analyse , Acide gras libre/sang , Lactates/sang , Mâle , Rats , Rat Wistar
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE